TFX:NYE-Teleflex Incorporated (USD)

EQUITY | Medical Instruments & Supplies | New York Stock Exchange

Last Closing

USD 223.87

Change

+7.48 (+3.46)%

Market Cap

USD 6.61B

Volume

0.31M

Analyst Target

USD 426.10
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Teleflex Inc designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

N/A

USD 66.90B
ALC Alcon AG

N/A

USD 38.91B
HYB New America High Income Closed..

N/A

USD 35.93B
RMD ResMed Inc

N/A

USD 27.76B
WST West Pharmaceutical Services I..

N/A

USD 27.24B
BAX Baxter International Inc

N/A

USD 20.44B
ATR AptarGroup Inc

N/A

USD 9.48B
STVN Stevanato Group SpA

N/A

USD 7.29B
BLCO Bausch + Lomb Corp

N/A

USD 5.19B
HAE Haemonetics Corporation

N/A

USD 4.30B

ETFs Containing TFX

RNMC First Trust Mid Cap US Eq.. 1.00 % 0.60 %

N/A

USD 0.02B
QRH:CA 0.00 % 1.20 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.21% 16% F 11% F
Dividend Return 0.14% 22% F 5% F
Total Return -10.08% 16% F 10% F
Trailing 12 Months  
Capital Gain -9.12% 26% F 18% F
Dividend Return 0.55% 30% F 5% F
Total Return -8.57% 26% F 16% F
Trailing 5 Years  
Capital Gain -25.91% 27% F 20% F
Dividend Return 2.25% 13% F 7% C-
Total Return -23.66% 27% F 15% F
Average Annual (5 Year Horizon)  
Capital Gain -6.63% 15% F 16% F
Dividend Return -6.21% 15% F 11% F
Total Return 0.42% 27% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 19.63% 75% C 57% F
Risk Adjusted Return -31.62% 15% F 12% F
Market Capitalization 6.61B 68% D+ 85% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 25.90 75% 24%
Price/Book Ratio 2.38 68% 35%
Price / Cash Flow Ratio 20.68 39% 16%
Price/Free Cash Flow Ratio 16.11 61% 22%
Management Effectiveness  
Return on Equity 8.45% 67% 51%
Return on Invested Capital 7.17% 67% 54%
Return on Assets 4.34% 68% 67%
Debt to Equity Ratio 38.90% 43% 68%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector